Ki-67 expression in anti-programmed cell death protein-1 antibody-bound CD8⁺ T cells as a predictor of clinical benefit.

ABSTRACT:

Aims

Developing predictive biomarkers for immune checkpoint inhibitors (ICIs) is important. Programmed cell death protein-1 (PD-1) receptor occupancy by anti-PD-1 antibodies on circulating T cells varies among patients. However, the association between the exhaustion of these antibody-bound T cells and the clinical efficacy of ICIs remains unknown. Therefore, the present study was aimed at evaluating this association.

Methods

This prospective cohort study included patients with advanced non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma (ESCC) who received pembrolizumab therapy. Peripheral blood samples were collected during the second cycle of chemotherapy. We analyzed the relationship between exhaustion markers in pembrolizumab-bound (PB) T cells and

SUBMITTER: Tsurui T 

PROVIDER: S-EPMC11920542 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature